Janus Henderson Group
IBER

Janus Henderson Group’s Ibere Pharmaceuticals IBER Stock Holding History

Janus Henderson Group’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-52,917
Closed -$534K – 2807
2022
Q4 		$534K Hold
52,917
– – ﹤0.01% 1684
2022
Q3 		$525K Buy
+52,917
New +$522K ﹤0.01% 1563

Janus Henderson Group's IBER Position: Q1 2023 in Review

Janus Henderson Group sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 52,917 shares — an estimated $534K sold.

Janus Henderson Group first reported a position in IBER in Q3 2022 and held it in 2 quarters. The position peaked at $534K in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

  • Janus Henderson Group reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Janus Henderson Group sold 52,917 Ibere Pharmaceuticals shares in Q1 2023, an estimated $534K.
  • Janus Henderson Group first reported a position in Ibere Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Janus Henderson Group's Ibere Pharmaceuticals position peaked at $534K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Janus Henderson Group's 13F filing for Q1 2023, filed 15 May 2023.